Response of human chronic myeloid leukemia cells to mitoxantrone cytotoxicity: potentiation by bepridil, a calcium channel antagonist.
The ability of bepridil, a calcium channel blocker, to potentiate the antitumor activity of mitoxantrone (MITO) in human chronic myeloid leukemia (CML) cells was evaluated. MITO and bepridil, when incubated alone with the CML cells for 4 h, indicated a dose-dependent increase in the inhibition of 3H-thymidine incorporation. Incorporation rate of the radiolabeled thymidine into DNA was used as a measure of cell growth. When the CML cells were exposed to MITO (1 microgram/ml) in the presence of bepridil (1 and 5 micrograms/ml), an enhancement in the inhibition of DNA biosynthesis was observed in 14 out of 17 human CML samples studied. This significant inhibition (p less than 0.001) of 3H-thymidine incorporation due to the combination was found to be completely irreversible. Bepridil was identified predominantly in the octanol phase in the octanol/water partitioning studies. This lipophilic property of drug response modulators was implicated in the observed increase in the intracellular uptake of anticancer drugs, which in turn led to an enhanced cytotoxicity correlating well with the MITO activity observed in this study. The results are suggestive of clinical utility of bepridil as an adjuvant to enhance the anticancer ability of MITO in the treatment of CML.
Parekh
H K
HK
Cancer Research Institute, Tata Memorial Centre, Parel, Bombay, India.
Shallom
J M
JM
Advani
S H
SH
Chitnis
M P
MP
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D015764:Bepridil / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004357:Drug Synergism; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D008942:Mitoxantrone / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D004273:DNA, Neoplasm; D015764:Bepridil; D008942:Mitoxantrone